UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|||
For the quarterly period ended June 30, 2004 |
|||
|
|
|
|
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|||
For the transition period from to |
|||
|
|
|
|
Commission file no. 333-59054-01 |
Chevron Phillips Chemical Company LLC
(Exact name of the Registrant as specified in its charter)
Delaware |
|
73-1590261 |
(State or other
jurisdiction of |
|
(I.R.S. Employer |
|
|
|
10001
Six Pines Drive |
||
(Address of principal executive offices, including zip code) |
||
|
|
|
(832) 813-4100 |
||
(Registrants telephone number, including area code) |
||
|
|
|
NONE |
||
(Former name, former address and former fiscal year if changed since last report) |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes o No ý
Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Act).
Yes o No ý
Chevron Phillips Chemical Company LLC
Index
2
Chevron Phillips Chemical Company LLC
Condensed Consolidated Statement of Operations
(Unaudited)
|
|
Three
months ended |
|
Six months
ended |
|
||||||||
Millions |
|
2004 |
|
2003 |
|
2004 |
|
2003 |
|
||||
Revenue |
|
|
|
|
|
|
|
|
|
||||
Net sales |
|
$ |
2,091 |
|
$ |
1,701 |
|
$ |
4,084 |
|
$ |
3,497 |
|
Equity in income of affiliates, net |
|
44 |
|
16 |
|
71 |
|
22 |
|
||||
Other income |
|
21 |
|
13 |
|
40 |
|
31 |
|
||||
Total revenue |
|
2,156 |
|
1,730 |
|
4,195 |
|
3,550 |
|
||||
|
|
|
|
|
|
|
|
|
|
||||
Costs and Expenses |
|
|
|
|
|
|
|
|
|
||||
Cost of goods sold |
|
1,922 |
|
1,539 |
|
3,720 |
|
3,314 |
|
||||
Selling, general and administrative |
|
106 |
|
127 |
|
210 |
|
227 |
|
||||
Research and development |
|
11 |
|
12 |
|
21 |
|
23 |
|
||||
Total costs and expenses |
|
2,039 |
|
1,678 |
|
3,951 |
|
3,564 |
|
||||
|
|
|
|
|
|
|
|
|
|
||||
Income (Loss) Before Interest and Taxes |
|
117 |
|
52 |
|
244 |
|
(14 |
) |
||||
|
|
|
|
|
|
|
|
|
|
||||
Interest income |
|
2 |
|
3 |
|
4 |
|
4 |
|
||||
Interest expense |
|
(19 |
) |
(19 |
) |
(37 |
) |
(35 |
) |
||||
|
|
|
|
|
|
|
|
|
|
||||
Income (Loss) Before Taxes |
|
100 |
|
36 |
|
211 |
|
(45 |
) |
||||
|
|
|
|
|
|
|
|
|
|
||||
Income taxes |
|
(3 |
) |
(1 |
) |
(6 |
) |
(2 |
) |
||||
|
|
|
|
|
|
|
|
|
|
||||
Net Income (Loss) |
|
97 |
|
35 |
|
205 |
|
(47 |
) |
||||
|
|
|
|
|
|
|
|
|
|
||||
Distributions on members preferred interests |
|
(5 |
) |
(5 |
) |
(11 |
) |
(11 |
) |
||||
|
|
|
|
|
|
|
|
|
|
||||
Income (Loss) Attributed to Members Interests |
|
$ |
92 |
|
$ |
30 |
|
$ |
194 |
|
$ |
(58 |
) |
See Notes to Condensed Consolidated Financial Statements.
3
Chevron Phillips Chemical Company LLC
Condensed Consolidated Balance Sheet
(Unaudited)
Millions |
|
June 30, |
|
December 31, |
|
||
|
|
|
|
|
|
||
ASSETS |
|
||||||
|
|
|
|
|
|
||
Current assets |
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
42 |
|
$ |
43 |
|
Accounts receivable, net |
|
1,041 |
|
862 |
|
||
Inventories |
|
654 |
|
700 |
|
||
Other current assets |
|
19 |
|
31 |
|
||
Total current assets |
|
1,756 |
|
1,636 |
|
||
|
|
|
|
|
|
||
Property, plant and equipment, net |
|
3,815 |
|
3,864 |
|
||
Investments in and advances to affiliates |
|
759 |
|
673 |
|
||
Other assets and deferred charges |
|
69 |
|
69 |
|
||
|
|
|
|
|
|
||
Total Assets |
|
$ |
6,399 |
|
$ |
6,242 |
|
|
|
|
|
|
|
||
LIABILITIES AND MEMBERS EQUITY |
|
||||||
|
|
|
|
|
|
||
Current liabilities |
|
|
|
|
|
||
Accounts payable |
|
$ |
761 |
|
$ |
667 |
|
Accrued income and other taxes |
|
44 |
|
54 |
|
||
Secured borrowings and other debt |
|
201 |
|
314 |
|
||
Other current liabilities |
|
160 |
|
149 |
|
||
Total current liabilities |
|
1,166 |
|
1,184 |
|
||
|
|
|
|
|
|
||
Long-term debt |
|
1,243 |
|
1,189 |
|
||
Other liabilities and deferred credits |
|
107 |
|
109 |
|
||
|
|
|
|
|
|
||
Total liabilities |
|
2,516 |
|
2,482 |
|
||
|
|
|
|
|
|
||
Members preferred interests |
|
250 |
|
250 |
|
||
|
|
|
|
|
|
||
Members capital |
|
3,606 |
|
3,478 |
|
||
Accumulated other comprehensive income |
|
27 |
|
32 |
|
||
|
|
|
|
|
|
||
Total Liabilities and Members Equity |
|
$ |
6,399 |
|
$ |
6,242 |
|
See Notes to Condensed Consolidated Financial Statements.
4
Chevron Phillips Chemical Company LLC
Condensed Consolidated Statement of Cash Flows
(Unaudited)
|
|
Six months
ended |
|
||||
Millions |
|
2004 |
|
2003 |
|
||
|
|
|
|
|
|
||
Cash Flows From Operating Activities |
|
|
|
|
|
||
Net income (loss) |
|
$ |
205 |
|
$ |
(47 |
) |
Adjustments to reconcile net income (loss) to net cash flows provided by operating activities |
|
|
|
|
|
||
Depreciation, amortization and retirements |
|
139 |
|
140 |
|
||
Undistributed equity in income of affiliates, net |
|
(59 |
) |
(17 |
) |
||
Changes in operating working capital |
|
(34 |
) |
(107 |
) |
||
Other operating cash flow activity |
|
1 |
|
34 |
|
||
Net cash flows provided by operating activities |
|
252 |
|
3 |
|
||
|
|
|
|
|
|
||
Cash Flows From Investing Activities |
|
|
|
|
|
||
Capital and investment expenditures |
|
(100 |
) |
(83 |
) |
||
Investments in and advances to Qatar Chemical Company Ltd. (Q-Chem) |
|
(18 |
) |
(76 |
) |
||
Net cash flows used in investing activities |
|
(118 |
) |
(159 |
) |
||
|
|
|
|
|
|
||
Cash Flows From Financing Activities |
|
|
|
|
|
||
Increase in commercial paper, net |
|
54 |
|
140 |
|
||
Increase (decrease) in secured borrowings, net |
|
(100 |
) |
10 |
|
||
Decrease in other debt, net |
|
(14 |
) |
|
|
||
Distributions on members preferred interests |
|
(39 |
) |
|
|
||
Other distributions to members |
|
(36 |
) |
|
|
||
Contributions from members |
|
|
|
32 |
|
||
Net cash flows provided by (used in) financing activities |
|
(135 |
) |
182 |
|
||
|
|
|
|
|
|
||
Net Increase (Decrease) in Cash and Cash Equivalents |
|
(1 |
) |
26 |
|
||
Cash and Cash Equivalents at Beginning of Period |
|
43 |
|
39 |
|
||
|
|
|
|
|
|
||
Cash and Cash Equivalents at End of Period |
|
$ |
42 |
|
$ |
65 |
|
See Notes to Condensed Consolidated Financial Statements.
5
Chevron Phillips Chemical Company LLC
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note 1. General Information
The company, through its subsidiaries and equity affiliates, manufactures and markets a wide range of petrochemicals on a worldwide basis, with manufacturing facilities in the United States, Puerto Rico, Singapore, China, South Korea, Saudi Arabia, Qatar, Mexico and Belgium. Chevron Phillips Chemical Company LLC is owned 50% each by ChevronTexaco Corporation (ChevronTexaco) and ConocoPhillips (collectively, the members).
The accompanying unaudited condensed consolidated financial statements include the accounts of Chevron Phillips Chemical Company LLC and its wholly-owned subsidiaries (collectively, CPChem), and should be read in conjunction with the consolidated financial statements included in CPChems Annual Report on Form 10-K for the year ended December 31, 2003. The financial statements and accompanying Managements Discussion and Analysis of Financial Condition and Results of Operations have been prepared in conformity with the rules and regulations of the Securities and Exchange Commission (the SEC). Some information and footnote disclosures required by generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. The financial statements include all normal recurring adjustments that CPChem considers necessary for a fair presentation. Certain amounts for prior periods may have been reclassified in order to conform to the current reporting presentation. Results for the three and six month periods ended June 30, 2004 are not necessarily indicative of future financial performance.
Note 2. New Accounting Pronouncements
Effective January 1, 2004, CPChem adopted Statement of Financial Accounting Standards No. 150, Accounting for Certain Financial Instruments with Characteristics of Both Liabilities and Equity, which establishes standards for how an issuer classifies and measures certain financial instruments that have characteristics of both a liability and of equity. Generally, it requires that an issuer classify such financial instruments as liabilities because they embody an obligation of the issuer. Because CPChem has no financial instruments outstanding that fall within the scope of this new standard, implementation of this standard did not have an impact on consolidated results of operations, financial position or liquidity. CPChems outstanding preferred members interests currently do not fall within the scope of this standard because they contain redemption provisions that create a conditional, rather than mandatory, obligation of CPChem. In the event that CPChems ratio of debt to total capitalization reaches a stated level, a portion of the outstanding preferred members interests will be reclassified as a liability.
The Financial Accounting Standards Board issued Interpretation No. 46 (revised December 2003), Consolidation of Variable Interest Entities, (FIN No. 46(R)) which provides guidance as to when a company is required to include in its financial statements the assets, liabilities and activities of a variable interest entity (a VIE). A VIE is generally a corporation, partnership, trust, or any other legal structure used for business purposes that either does not have equity investors with voting rights or that has equity investors that do not provide sufficient financial resources for the entity to support its activities. FIN No. 46(R) requires a VIE to be consolidated by a company if that company is subject to a majority of the risk of loss from the activities of the VIE or is entitled to receive a majority of the residual returns of the VIE. FIN No. 46(R) also requires disclosures about VIEs that are not required to be consolidated by a company, but in which the company has a significant variable interest. The consolidation requirements of FIN No. 46(R) apply immediately
6
to VIEs created after December 31, 2003, and for CPChem, which is considered to be a nonpublic entity as it relates to FIN No. 46(R), the consolidation requirements will apply to pre-existing VIEs effective January 1, 2005. CPChem believes that FIN No. 46(R) will not require the consolidation of any existing VIE into CPChems consolidated financial statements.
Note 3. Comprehensive Income (Loss)
|
|
Three
months ended |
|
Six months
ended |
|
||||||||
Millions |
|
2004 |
|
2003 |
|
2004 |
|
2003 |
|
||||
|
|
|
|
|
|
|
|
|
|
||||
Net income (loss) |
|
$ |
97 |
|
$ |
35 |
|
$ |
205 |
|
$ |
(47 |
) |
Foreign currency translation adjustments |
|
(2 |
) |
5 |
|
(5 |
) |
9 |
|
||||
Minimum pension liability adjustment |
|
|
|
|
|
|
|
(3 |
) |
||||
Comprehensive income (loss) |
|
$ |
95 |
|
$ |
40 |
|
$ |
200 |
|
$ |
(41 |
) |
Note 4. Postretirement Benefits Information
CPChem expects to contribute a minimum of $39 million to its pension plans for employee pension benefits during 2004. No such contributions were made during the first half of 2004.
Net periodic benefit costs for pension and other postretirement benefits follow:
|
|
Three
months ended |
|
Six months
ended |
|
||||||||
Millions |
|
2004 |
|
2003 |
|
2004 |
|
2003 |
|
||||
Pension Benefit Costs |
|
|
|
|
|
|
|
|
|
||||
Service cost on benefits earned |
|
$ |
6 |
|
$ |
6 |
|
$ |
11 |
|
$ |
11 |
|
Interest cost on projected benefit obligations |
|
4 |
|
5 |
|
9 |
|
9 |
|
||||
Expected return on plan assets |
|
(3 |
) |
(3 |
) |
(6 |
) |
(5 |
) |
||||
Amortization of prior service costs |
|
3 |
|
3 |
|
6 |
|
6 |
|
||||
Net actuarial loss |
|
1 |
|
|
|
1 |
|
|
|
||||
Net periodic benefit cost |
|
$ |
11 |
|
$ |
11 |
|
$ |
21 |
|
$ |
21 |
|
|
|
|
|
|
|
|
|
|
|
||||
Other Postretirement Benefit Costs |
|
|
|
|
|
|
|
|
|
||||
Service cost on benefits earned |
|
$ |
1 |
|
$ |
1 |
|
$ |
1 |
|
$ |
2 |
|
Interest cost on projected benefit obligations |
|
1 |
|
2 |
|
2 |
|
3 |
|
||||
Expected return on plan assets |
|
(1 |
) |
|
|
(1 |
) |
|
|
||||
Amortization of prior service costs |
|
1 |
|
|
|
2 |
|
1 |
|
||||
Net periodic benefit cost |
|
$ |
2 |
|
$ |
3 |
|
$ |
4 |
|
$ |
6 |
|
Note 5. Taxes
CPChem is treated as a flow-through entity for federal income tax and for most state income tax purposes whereby each member is taxable on its respective share of income and loss. However, CPChem is directly liable for federal and state income taxes and franchise taxes on certain separate legal entities and for any foreign taxes incurred. CPChem follows the liability method of accounting for these income taxes.
CPChem is required to make quarterly distributions to its members in amounts representing the liability for combined federal and state income tax calculated at specified rates based on CPChems estimate of federal taxable income. In the second quarter of 2004, CPChem made a $36 million tax distribution to its members. In addition, a $30 million tax distribution was accrued in Other Current Liabilities at June 30, 2004 and will be paid in the third quarter of 2004.
7
Note 6. Investments
Qatar Chemical Company Ltd. (Q-Chem)
Qatar Chemical Company Ltd. (Q-Chem), a joint venture company, was formed in 1998 to develop a petrochemical complex in Qatar. The complex has commenced commercial operation and is in the final stages of project completion. Q-Chem fully utilized the $750 million available under its 1999 senior bank financing agreement for the construction of the complex. CPChem is required to fund any remaining construction costs, initial working capital requirements, and certain operating and debt service reserve fund requirements through advances under a subordinated loan agreement with Q-Chem. No advances were made during the first six months of 2004 under the subordinated loan agreement. Under the terms of the agreement, CPChem expects to advance Q-Chem approximately $10 million in 2004. The obligation to make advances under the subordinated loan agreement will terminate upon completion of the facilities, as defined in the bank financing agreements. It is expected that project completion will be achieved by October 31, 2004.
Under the terms of a bank financing completion guarantee, the banks have the right to demand from each Q-Chem co-venturer, on a pro rata basis, funds to cover the debt service requirements of Q-Chem that are due after August 1, 2003 until project completion. CPChem subscribed to $18 million of additional shares of Q-Chem in the first six months of 2004 to fund its 49% share of the debt service requirements of Q-Chem that were due in that period. Furthermore, if the project is not completed on time, the banks have the right to demand from each co-venturer, on a pro rata basis, repayment of all outstanding principal and interest. The banks have recently unanimously agreed to extend the project completion deadline from August 31, 2004 to October 31, 2004. After the project is completed, the bank financing is non-recourse with respect to the co-venturers, with the exception of the contingent obligations described below. Total principal and interest outstanding under Q-Chems bank financing was $677 million at June 30, 2004.
After the project is completed, CPChem has agreed to provide up to $75 million of loans to Q-Chem if there is insufficient cash to pay the minimum debt service amount on the bank financing. CPChem believes it is unlikely that funding under this support agreement will be required.
CPChem also agreed to provide loans to Q-Chem for a period of up to 33 months following commencement of commercial operation as defined in the bank financing agreements if there is insufficient cash to pay the target debt service amount. These loans are limited to an amount not greater than lost operating margins resulting from sales volumes being less than design capacity. CPChem believes that any funding required under this support agreement is unlikely to have a material adverse effect on CPChems consolidated results of operations, financial position or liquidity.
CPChems rights under the subordinated loan agreement and the other contingent loan agreements related to Q-Chem described above are subordinate to Q-Chems senior bank debt. Security interests in the notes related to such loans have been granted to the banks to support the terms of subordination.
CPChem records its 49% share of Q-Chems operating results using the equity method. Q-Chem is considered to be a VIE under the provisions of FIN No. 46(R). CPChems maximum exposure to loss per FIN No. 46(R) was $672 million at June 30, 2004. This amount represents the total of CPChems carrying value of its investment in Q-Chem, advances and related interest receivable from Q-Chem under the subordinated loan agreement and CPChems pro rata share of Q-Chems outstanding bank financing and associated accrued interest. CPChem believes the likelihood of incurring any substantial portion of the stated maximum exposure to loss is remote.
8
Saudi Chevron Phillips Company
Saudi Chevron Phillips Company (Saudi Chevron Phillips) is a joint venture company that owns facilities in Al Jubail, Saudi Arabia. Saudi Chevron Phillips was financed with loans from commercial banks and a Saudi Arabian governmental agency. The loans are payable in semiannual installments and mature in 2008. At June 30, 2004, Chevron Phillips Chemical Company LLC and the Saudi Arabian co-venturer each had a several obligation of up to $25 million to fund debt service requirements in the event Saudi Chevron Phillips had insufficient cash to pay its debt service requirements. In addition, the subsidiary of Chevron Phillips Chemical Company LLC which directly owns the 50% interest in Saudi Chevron Phillips, along with the other co-venturer, have each also guaranteed their respective 50% share of certain loans payable by Saudi Chevron Phillips to a Saudi Arabian governmental agency. Chevron Phillips Chemical Company LLC is not a party to this guarantee. These loans totaled $80 million (gross) at June 30, 2004. CPChem believes it is unlikely that any funding under the debt service obligation or the guarantee will be required.
Jubail Chevron Phillips Company
Jubail Chevron Phillips Company (JCP), a 50%-owned joint venture company, was formed in 2003 to develop an integrated styrene facility in Al Jubail, Saudi Arabia. The 1.6 billion-pound-per-year facility, to be built on a site adjacent to the existing aromatics complex owned by Saudi Chevron Phillips, will include feed fractionation, an olefins cracker, and ethylbenzene and styrene monomer process units. Construction of the JCP facility will be in conjunction with an expansion of Saudi Chevron Phillips benzene plant, together called the JCP Project. Approval of the estimated $1.2 billion project was granted by CPChems Board of Directors and the co-venturer in 2004, with construction expected to begin in mid-2005. Operational start-up is anticipated in late 2007. The project will be financed through equity contributions and subordinated loans from the co-venturers, and limited recourse loans from commercial banks and Saudi Arabian governmental agencies.
Summarized Financial Information
Summarized financial information, shown at 100%, for Q-Chem, Saudi Chevron Phillips and all other equity investments of CPChem in the aggregate follows:
|
|
Three
months ended |
|
Six months
ended |
|
||||||||
Millions |
|
2004 |
|
2003 |
|
2004 |
|
2003 |
|
||||
|
|
|
|
|
|
|
|
|
|
||||
Q-Chem |
|
|
|
|
|
|
|
|
|
||||
Revenues |
|
$ |
70 |
|
$ |
12 |
|
$ |
133 |
|
$ |
12 |
|
Income (loss) before income taxes |
|
29 |
|
(15 |
) |
47 |
|
(21 |
) |
||||
Net income (loss) |
|
29 |
|
(15 |
) |
47 |
|
(21 |
) |
||||
|
|
|
|
|
|
|
|
|
|
||||
Saudi Chevron Phillips |
|
|
|
|
|
|
|
|
|
||||
Revenues |
|
148 |
|
117 |
|
259 |
|
210 |
|
||||
Income before income taxes |
|
60 |
|
44 |
|
93 |
|
68 |
|
||||
Net income |
|
60 |
|
44 |
|
93 |
|
68 |
|
||||
|
|
|
|
|
|
|
|
|
|
||||
Other equity investments |
|
|
|
|
|
|
|
|
|
||||
Revenues |
|
219 |
|
171 |
|
424 |
|
327 |
|
||||
Income (loss) before income taxes |
|
2 |
|
(1 |
) |
7 |
|
|
|
||||
Net income (loss) |
|
1 |
|
(1 |
) |
5 |
|
(1 |
) |
||||
9
Note 7. Trade Receivables Securitization
CPChem had $200 million of secured borrowings outstanding at June 30, 2004 and $300 million outstanding at December 31, 2003 under trade receivables securitization agreements. These borrowings were classified as short-term and were secured by $512 million and $459 million of trade receivables, respectively. In the second quarter of 2004, CPChem renewed its $300 million trade receivables securitization agreement on terms substantially identical to those of the prior agreement. The new agreement expires on May 17, 2005.
Note 8. Contingent Liabilities
In the case of known contingent liabilities, CPChem records an undiscounted liability when a loss is probable and the amount can be reasonably estimated. These liabilities are not reduced for potential insurance recoveries. If applicable, undiscounted receivables are recorded for probable insurance or other third-party recoveries. Based on currently available information, CPChem believes it is remote that future costs related to known contingent liabilities will exceed current accruals by an amount that would have a material adverse effect on consolidated results of operations, financial position or liquidity.
As facts concerning contingent liabilities become known, CPChem reassesses its position with respect to accrued liabilities and other potential exposures. Estimates that are particularly sensitive to future change include legal matters and contingent liabilities for environmental remediation. Estimated future environmental remediation costs are subject to change due to such factors as the unknown magnitude of cleanup costs, prospective changes in laws and regulations, the unknown timing and extent of remedial actions that may be required and the determination of CPChems liability in proportion to other responsible parties. Estimated future costs related to legal matters are subject to change as events occur and as additional information becomes available during administrative and litigation processes.
CPChem is a party to a number of legal proceedings that arose in the ordinary course of business for which, in many instances, no provision has been made in the financial statements. While the final outcome of these proceedings cannot be predicted with certainty, CPChem believes that none of these proceedings, when resolved, will have a material adverse effect on consolidated results of operations, financial position or liquidity.
Electricity Deregulation
Legislation for electricity deregulation for the Electricity Reliability Council of Texas (ERCOT) area of Texas was enacted in 1999, allowing retail electricity consumers to choose electricity providers effective January 1, 2002. This legislation also allows utilities to file an application with the Public Utility Council of Texas (PUCT) for determination and reimbursement of costs, if any, associated with the implementation of this legislation. Included in these costs are certain environmental expenses and costs associated with stranded assets. Stranded asset costs are those associated with the utility asset devaluation that may have occurred due to the legislation. Once determined, these costs are paid by electricity consumers under PUCT-mandated procedures.
CenterPoint Energy Houston Electric LLC (CenterPoint), which previously provided electricity to certain CPChem manufacturing facilities, filed its application for such determination with the PUCT on March 31, 2004. A number of consumers and organizations representing consumers have intervened in the PUCT proceedings to object to the claims in CenterPoints application. The PUCT is expected to rule on CenterPoints claim in the Fall of 2004.
10
If the PUCT determines that CenterPoint is entitled to recover some or all of the costs claimed in its application, CPChem would receive a monthly charge added to its electricity cost over an extended period of time to pay for such reimbursement. Based on CenterPoints application, it is currently anticipated that the additional monthly cost to CPChem, if any, that is approved by the PUCT, will not have a material adverse effect on consolidated results of operations, financial position or liquidity.
Note 9. Guarantees and Indemnifications
Guarantees
CPChems headquarters building is leased under a synthetic lease agreement entered into in 2002. A synthetic lease is a lease that qualifies as an operating lease for financial accounting purposes and as a capital lease for tax accounting purposes. The lease contains a fixed price purchase option and a residual guarantee. The purchase option price was considered to be the fair market value of the building at the inception of the lease. If CPChem does not exercise the purchase option upon the expiration of the lease in 2007, CPChem has an obligation to pay the lessor the shortfall, if any, in the proceeds realized from the sale of the building to a third party relative to the purchase option price, not to exceed $27 million. CPChem is entitled to receive any proceeds from the sale of the building that are in excess of the purchase option price. While it is not possible to predict with certainty the amount, if any, that CPChem would be required to pay or be entitled to receive should the building be sold to a third party upon the expiration of the lease, CPChem believes that the amount paid or received would not be material to consolidated results of operations, financial position or liquidity.
See also Note 6 for a discussion of certain guarantees related to Q-Chem and Saudi Chevron Phillips.
Indemnifications
As part of CPChems ongoing business operations and consistent with generally accepted and recognized industry practice, CPChem enters into numerous agreements with other parties which apportion future risks between the parties to the transaction or relationship governed by the agreements. One method of apportioning risk is the inclusion of provisions requiring one party to indemnify the other party against losses that might be incurred in the future. Many of CPChems agreements, including technology license agreements, contain indemnities that require CPChem to perform certain acts, such as defending certain licensees against patent infringement claims of others, as a result of the occurrence of a triggering event or condition.
The nature of these indemnity obligations are diverse and numerous and each has different terms, business purposes, and triggering events or conditions. Consistent with customary business practice, any particular indemnity obligation incurred is the result of a negotiated transaction or contractual relationship for which CPChem has accepted a certain level of risk in return for a financial or other type of benefit. In addition, the indemnities in each agreement vary widely in their definitions of both the triggering event and the resulting obligation, which is contingent upon that triggering event.
11
With regard to indemnifications, CPChems risk management philosophy is to limit risk in any transaction or relationship to the maximum extent reasonable in relation to commercial and other considerations. Before accepting any indemnity obligation, consideration is given to, among other things, the remoteness of the possibility that the triggering event will occur, the potential costs to perform under any resulting indemnity obligation, possible actions to reduce the likelihood of a triggering event or to reduce the costs of performing under the indemnity obligation, any indemnifications by unrelated third parties, insurance coverage that may be available to offset the cost of the indemnity obligation, and the benefits from the transaction or relationship.
Because many of CPChems indemnity obligations are not limited in duration or potential monetary exposure, CPChem cannot reasonably calculate the maximum potential amount of future payments that could possibly be paid under the indemnity obligations stemming from all of CPChems existing agreements. In the case of known contingent liabilities, however, CPChem records an undiscounted liability when a loss is probable and the amount can be reasonably estimated.
CPChem is not aware of the occurrence of any triggering event or condition that would have a material adverse impact on consolidated results of operations, financial position or liquidity as a result of an indemnity obligation arising from such triggering event or condition.
Note 10. Segment Information
Financial information by segment follows:
Millions |
|
Olefins
& |
|
Aromatics
& |
|
Specialty |
|
Corporate, |
|
Consolidated |
|
|||||
Three months ended June 30, 2004 |
|
|
|
|
|
|
|
|
|
|
|
|||||
Net sales external |
|
$ |
1,258 |
|
$ |
708 |
|
$ |
125 |
|
$ |
|
|
$ |
2,091 |
|
Net sales inter-segment |
|
59 |
|
|
|
1 |
|
(60 |
) |
|
|
|||||
Income (loss) before interest & taxes |
|
56 |
|
48 |
|
19 |
|
(6 |
) |
117 |
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Three months ended June 30, 2003 |
|
|
|
|
|
|
|
|
|
|
|
|||||
Net sales external |
|
1,010 |
|
590 |
|
101 |
|
|
|
1,701 |
|
|||||
Net sales inter-segment |
|
77 |
|
34 |
|
1 |
|
(112 |
) |
|
|
|||||
Income (loss) before interest & taxes |
|
35 |
|
20 |
|
10 |
|
(13 |
) |
52 |
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Six months ended June 30, 2004 |
|
|
|
|
|
|
|
|
|
|
|
|||||
Net sales external |
|
2,497 |
|
1,347 |
|
240 |
|
|
|
4,084 |
|
|||||
Net sales inter-segment |
|
120 |
|
|
|
1 |
|
(121 |
) |
|
|
|||||
Income (loss) before interest & taxes |
|
159 |
|
62 |
|
34 |
|
(11 |
) |
244 |
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Six months ended June 30, 2003 |
|
|
|
|
|
|
|
|
|
|
|
|||||
Net sales external |
|
2,036 |
|
1,260 |
|
201 |
|
|
|
3,497 |
|
|||||
Net sales inter-segment |
|
145 |
|
76 |
|
1 |
|
(222 |
) |
|
|
|||||
Income (loss) before interest & taxes |
|
(40 |
) |
23 |
|
20 |
|
(17 |
) |
(14 |
) |
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Total assets June 30, 2004 |
|
3,870 |
|
1,915 |
|
486 |
|
128 |
|
6,399 |
|
|||||
Total assets December 31, 2003 |
|
3,746 |
|
1,849 |
|
496 |
|
151 |
|
6,242 |
|
|||||
12
Note 11. Condensed Consolidating Financial Statements
Condensed consolidating financial statements follow. This information is presented in accordance with SEC rules and regulations as they relate to the debt jointly and severally issued by Chevron Phillips Chemical Company LLC and Chevron Phillips Chemical Company LP.
The LLC is the non-operating parent holding company. The LP is the primary U.S. operating company. Other Entities is principally comprised of foreign operations and the holding companies that have direct ownership of the LP. These condensed consolidating financial statements were prepared using the equity method of accounting for investments.
Chevron Phillips Chemical Company LLC
Condensed Consolidating Statement of Operations
For the three months ended June 30, 2004
(Unaudited)
Millions |
|
LLC |
|
LP |
|
Other |
|
Eliminations |
|
Total |
|
|||||
Revenue |
|
|
|
|
|
|
|
|
|
|
|
|||||
Net sales |
|
$ |
|
|
$ |
1,861 |
|
$ |
356 |
|
$ |
(126 |
) |
$ |
2,091 |
|
Equity in income of affiliates, net |
|
118 |
|
1 |
|
89 |
|
(164 |
) |
44 |
|
|||||
Other income |
|
|
|
15 |
|
21 |
|
(15 |
) |
21 |
|
|||||
Total revenue |
|
118 |
|
1,877 |
|
466 |
|
(305 |
) |
2,156 |
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Costs and Expenses |
|
|
|
|
|
|
|
|
|
|
|
|||||
Cost of goods sold |
|
|
|
1,715 |
|
322 |
|
(115 |
) |
1,922 |
|
|||||
Selling, general and administrative |
|
|
|
111 |
|
21 |
|
(26 |
) |
106 |
|
|||||
Research and development |
|
|
|
11 |
|
|
|
|
|
11 |
|
|||||
Total costs and expenses |
|
|
|
1,837 |
|
343 |
|
(141 |
) |
2,039 |
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Income Before Interest and Taxes |
|
118 |
|
40 |
|
123 |
|
(164 |
) |
117 |
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Interest income |
|
|
|
5 |
|
2 |
|
(5 |
) |
2 |
|
|||||
Interest expense |
|
(21 |
) |
(1 |
) |
(2 |
) |
5 |
|
(19 |
) |
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Income Before Taxes |
|
97 |
|
44 |
|
123 |
|
(164 |
) |
100 |
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Income taxes |
|
|
|
|
|
(3 |
) |
|
|
(3 |
) |
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Net Income |
|
97 |
|
44 |
|
120 |
|
(164 |
) |
97 |
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Distributions on members preferred interests |
|
(5 |
) |
|
|
|
|
|
|
(5 |
) |
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Income Attributed to Members Interests |
|
$ |
92 |
|
$ |
44 |
|
$ |
120 |
|
$ |
(164 |
) |
$ |
92 |
|
13
Note 11. Condensed Consolidating Financial Statements (continued)
Chevron Phillips Chemical Company LLC
Condensed Consolidating Statement of Operations
For the three months ended June 30, 2003
(Unaudited)
Millions |
|
LLC |
|
LP |
|
Other |
|
Eliminations |
|
Total |
|
|||||
Revenue |
|
|
|
|
|
|
|
|
|
|
|
|||||
Net sales |
|
$ |
|
|
$ |
1,494 |
|
$ |
296 |
|
$ |
(89 |
) |
$ |
1,701 |
|
Equity in income of affiliates, net |
|
55 |
|
2 |
|
53 |
|
(94 |
) |
16 |
|
|||||
Other income |
|
|
|
15 |
|
10 |
|
(12 |
) |
13 |
|
|||||
Total revenue |
|
55 |
|
1,511 |
|
359 |
|
(195 |
) |
1,730 |
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Costs and Expenses |
|
|
|
|
|
|
|
|
|
|
|
|||||
Cost of goods sold |
|
|
|
1,339 |
|
282 |
|
(82 |
) |
1,539 |
|
|||||
Selling, general and administrative |
|
|
|
124 |
|
22 |
|
(19 |
) |
127 |
|
|||||
Research and development |
|
|
|
12 |
|
|
|
|
|
12 |
|
|||||
Total costs and expenses |
|
|
|
1,475 |
|
304 |
|
(101 |
) |
1,678 |
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Income Before Interest and Taxes |
|
55 |
|
36 |
|
55 |
|
(94 |
) |
52 |
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Interest income |
|
|
|
3 |
|
3 |
|
(3 |
) |
3 |
|
|||||
Interest expense |
|
(20 |
) |
(1 |
) |
(1 |
) |
3 |
|
(19 |
) |
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Income Before Taxes |
|
35 |
|
38 |
|
57 |
|
(94 |
) |
36 |
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Income taxes |
|
|
|
|
|
(1 |
) |
|
|
(1 |
) |
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Net Income |
|
35 |
|
38 |
|
56 |
|
(94 |
) |
35 |
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Distributions on members preferred interests |
|
(5 |
) |
|
|
|
|
|
|
(5 |
) |
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Income Attributed to Members Interests |
|
$ |
30 |
|
$ |
38 |
|
$ |
56 |
|
$ |
(94 |
) |
$ |
30 |
|
14
Note 11. Condensed Consolidating Financial Statements (continued)
Chevron Phillips Chemical Company LLC
Condensed Consolidating Statement of Operations
For the six months ended June 30, 2004
(Unaudited)
Millions |
|
LLC |
|
LP |
|
Other |
|
Eliminations |
|
Total |
|
|||||
Revenue |
|
|
|
|
|
|
|
|
|
|
|
|||||
Net sales |
|
$ |
|
|
$ |
3,656 |
|
$ |
687 |
|
$ |
(259 |
) |
$ |
4,084 |
|
Equity in income of affiliates, net |
|
246 |
|
1 |
|
185 |
|
(361 |
) |
71 |
|
|||||
Other income |
|
|
|
30 |
|
43 |
|
(33 |
) |
40 |
|
|||||
Total revenue |
|
246 |
|
3,687 |
|
915 |
|
(653 |
) |
4,195 |
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Costs and Expenses |
|
|
|
|
|
|
|
|
|
|
|
|||||
Cost of goods sold |
|
|
|
3,343 |
|
616 |
|
(239 |
) |
3,720 |
|
|||||
Selling, general and administrative |
|
|
|
219 |
|
44 |
|
(53 |
) |
210 |
|
|||||
Research and development |
|
|
|
21 |
|
|
|
|
|
21 |
|
|||||
Total costs and expenses |
|
|
|
3,583 |
|
660 |
|
(292 |
) |
3,951 |
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Income Before Interest and Taxes |
|
246 |
|
104 |
|
255 |
|
(361 |
) |
244 |
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Interest income |
|
|
|
9 |
|
4 |
|
(9 |
) |
4 |
|
|||||
Interest expense |
|
(41 |
) |
(1 |
) |
(4 |
) |
9 |
|
(37 |
) |
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Income Before Taxes |
|
205 |
|
112 |
|
255 |
|
(361 |
) |
211 |
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Income taxes |
|
|
|
|
|
(6 |
) |
|
|
(6 |
) |
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Net Income |
|
205 |
|
112 |
|
249 |
|
(361 |
) |
205 |
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Distributions on members preferred interests |
|
(11 |
) |
|
|
|
|
|
|
(11 |
) |
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Income Attributed to Members Interests |
|
$ |
194 |
|
$ |
112 |
|
$ |
249 |
|
$ |
(361 |
) |
$ |
194 |
|
15
Note 11. Condensed Consolidating Financial Statements (continued)
Chevron Phillips Chemical Company LLC
Condensed Consolidating Statement of Operations
For the six months ended June 30, 2003
(Unaudited)
Millions |
|
LLC |
|
LP |
|
Other |
|
Eliminations |
|
Total |
|
|||||
Revenue |
|
|
|
|
|
|
|
|
|
|
|
|||||
Net sales |
|
$ |
|
|
$ |
3,095 |
|
$ |
614 |
|
$ |
(212 |
) |
$ |
3,497 |
|
Equity in income (loss) of affiliates, net |
|
(9 |
) |
(1 |
) |
(43 |
) |
75 |
|
22 |
|
|||||
Other income |
|
|
|
43 |
|
42 |
|
(54 |
) |
31 |
|
|||||
Total revenue |
|
(9 |
) |
3,137 |
|
613 |
|
(191 |
) |
3,550 |
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Costs and Expenses |
|
|
|
|
|
|
|
|
|
|
|
|||||
Cost of goods sold |
|
|
|
2,937 |
|
572 |
|
(195 |
) |
3,314 |
|
|||||
Selling, general and administrative |
|
|
|
248 |
|
50 |
|
(71 |
) |
227 |
|
|||||
Research and development |
|
|
|
23 |
|
|
|
|
|
23 |
|
|||||
Total costs and expenses |
|
|
|
3,208 |
|
622 |
|
(266 |
) |
3,564 |
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Income (Loss) Before Interest and Taxes |
|
(9 |
) |
(71 |
) |
(9 |
) |
75 |
|
(14 |
) |
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Interest income |
|
|
|
6 |
|
4 |
|
(6 |
) |
4 |
|
|||||
Interest expense |
|
(38 |
) |
(1 |
) |
(2 |
) |
6 |
|
(35 |
) |
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Income (Loss) Before Taxes |
|
(47 |
) |
(66 |
) |
(7 |
) |
75 |
|
(45 |
) |
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Income taxes |
|
|
|
|
|
(2 |
) |
|
|
(2 |
) |
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Net Income (Loss) |
|
(47 |
) |
(66 |
) |
(9 |
) |
75 |
|
(47 |
) |
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Distributions on members preferred interests |
|
(11 |
) |
|
|
|
|
|
|
(11 |
) |
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Income (Loss) Attributed to Members Interests |
|
$ |
(58 |
) |
$ |
(66 |
) |
$ |
(9 |
) |
$ |
75 |
|
$ |
(58 |
) |
16
Note 11. Condensed Consolidating Financial Statements (continued)
Chevron Phillips Chemical Company LLC
Condensed Consolidating Balance Sheet
June 30, 2004
(Unaudited)
Millions |
|
LLC |
|
LP |
|
Other |
|
Eliminations |
|
Total |
|
|||||
Current assets |
|
|
|
|
|
|
|
|
|
|
|
|||||
Cash and cash equivalents |
|
$ |
|
|
$ |
7 |
|
$ |
35 |
|
$ |
|
|
$ |
42 |
|
Accounts receivable, net |
|
205 |
|
724 |
|
838 |
|
(726 |
) |
1,041 |
|
|||||
Inventories |
|
|
|
501 |
|
153 |
|
|
|
654 |
|
|||||
Other current assets |
|
1 |
|
12 |
|
6 |
|
|
|
19 |
|
|||||
Total current assets |
|
206 |
|
1,244 |
|
1,032 |
|
(726 |
) |
1,756 |
|
|||||
Property, plant and equipment, net |
|
|
|
3,489 |
|
326 |
|
|
|
3,815 |
|
|||||
Investments in and advances to affiliates |
|
6,114 |
|
65 |
|
5,617 |
|
(11,037 |
) |
759 |
|
|||||
Other assets and deferred charges |
|
20 |
|
1,221 |
|
28 |
|
(1,200 |
) |
69 |
|
|||||
Total Assets |
|
$ |
6,340 |
|
$ |
6,019 |
|
$ |
7,003 |
|
$ |
(12,963 |
) |
$ |
6,399 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Current liabilities |
|
|
|
|
|
|
|
|
|
|
|
|||||
Accounts payable |
|
$ |
31 |
|
$ |
861 |
|
$ |
595 |
|
$ |
(726 |
) |
$ |
761 |
|
Secured borrowings and other debt |
|
|
|
1 |
|
200 |
|
|
|
201 |
|
|||||
Other current liabilities |
|
47 |
|
136 |
|
21 |
|
|
|
204 |
|
|||||
Total current liabilities |
|
78 |
|
998 |
|
816 |
|
(726 |
) |
1,166 |
|
|||||
Long-term debt |
|
1,234 |
|
9 |
|
|
|
|
|
1,243 |
|
|||||
Other liabilities and deferred credits |
|
1,172 |
|
103 |
|
32 |
|
(1,200 |
) |
107 |
|
|||||
Total liabilities |
|
2,484 |
|
1,110 |
|
848 |
|
(1,926 |
) |
2,516 |
|
|||||
Members preferred interests |
|
250 |
|
|
|
|
|
|
|
250 |
|
|||||
Members capital |
|
3,606 |
|
4,909 |
|
6,128 |
|
(11,037 |
) |
3,606 |
|
|||||
Accumulated other comprehensive income |
|
|
|
|
|
27 |
|
|
|
27 |
|
|||||
Total Liabilities and Members Equity |
|
$ |
6,340 |
|
$ |
6,019 |
|
$ |
7,003 |
|
$ |
(12,963 |
) |
$ |
6,399 |
|
17
Note 11. Condensed Consolidating Financial Statements (continued)
Chevron Phillips Chemical Company LLC
Condensed Consolidating Balance Sheet
December 31, 2003
Millions |
|
LLC |
|
LP |
|
Other |
|
Eliminations |
|
Total |
|
|||||
Current assets |
|
|
|
|
|
|
|
|
|
|
|
|||||
Cash and cash equivalents |
|
$ |
|
|
$ |
12 |
|
$ |
31 |
|
$ |
|
|
$ |
43 |
|
Accounts receivable, net |
|
203 |
|
436 |
|
698 |
|
(475 |
) |
862 |
|
|||||
Inventories |
|
|
|
565 |
|
135 |
|
|
|
700 |
|
|||||
Other current assets |
|
1 |
|
24 |
|
6 |
|
|
|
31 |
|
|||||
Total current assets |
|
204 |
|
1,037 |
|
870 |
|
(475 |
) |
1,636 |
|
|||||
Property, plant and equipment, net |
|
|
|
3,538 |
|
326 |
|
|
|
3,864 |
|
|||||
Investments in and advances to affiliates |
|
5,841 |
|
66 |
|
5,402 |
|
(10,636 |
) |
673 |
|
|||||
Other assets and deferred charges |
|
22 |
|
1,156 |
|
26 |
|
(1,135 |
) |
69 |
|
|||||
Total Assets |
|
$ |
6,067 |
|
$ |
5,797 |
|
$ |
6,624 |
|
$ |
(12,246 |
) |
$ |
6,242 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Current liabilities |
|
|
|
|
|
|
|
|
|
|
|
|||||
Accounts payable |
|
$ |
10 |
|
$ |
755 |
|
$ |
377 |
|
$ |
(475 |
) |
$ |
667 |
|
Secured borrowings and other debt |
|
|
|
1 |
|
313 |
|
|
|
314 |
|
|||||
Other current liabilities |
|
45 |
|
141 |
|
17 |
|
|
|
203 |
|
|||||
Total current liabilities |
|
55 |
|
897 |
|
707 |
|
(475 |
) |
1,184 |
|
|||||
Long-term debt |
|
1,179 |
|
10 |
|
|
|
|
|
1,189 |
|
|||||
Other liabilities and deferred credits |
|
1,105 |
|
108 |
|
31 |
|
(1,135 |
) |
109 |
|
|||||
Total liabilities |
|
2,339 |
|
1,015 |
|
738 |
|
(1,610 |
) |
2,482 |
|
|||||
Members preferred interests |
|
250 |
|
|
|
|
|
|
|
250 |
|
|||||
Members capital |
|
3,478 |
|
4,782 |
|
5,854 |
|
(10,636 |
) |
3,478 |
|
|||||
Accumulated other comprehensive income |
|
|
|
|
|
32 |
|
|
|
32 |
|
|||||
Total Liabilities and Members Equity |
|
$ |
6,067 |
|
$ |
5,797 |
|
$ |
6,624 |
|
$ |
(12,246 |
) |
$ |
6,242 |
|
18
Note 11. Condensed Consolidating Financial Statements (continued)
Chevron Phillips Chemical Company LLC
Condensed Consolidating Statement of Cash Flows
For the six months ended June 30, 2004
(Unaudited)
Millions |
|
LLC |
|
LP |
|
Other |
|
Eliminations |
|
Total |
|
||||||||||
Cash Flows From Operating Activities |
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Net income |
|
$ |
205 |
|
$ |
112 |
|
$ |
249 |
|
$ |
(361 |
) |
$ |
205 |
|
|||||
Adjustments to reconcile net income to net cash flows provided by operating activities |
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Depreciation, amortization and retirements |
|
|
|
128 |
|
11 |
|
|
|
139 |
|
||||||||||
Undistributed equity in income of affiliates, net |
|
(243 |
) |
(1 |
) |
(173 |
) |
358 |
|
(59 |
) |
||||||||||
Changes in operating working capital |
|
19 |
|
(95 |
) |
42 |
|
|
|
(34 |
) |
||||||||||
Other operating cash flow activity |
|
70 |
|
(69 |
) |
|
|
|
|
1 |
|
||||||||||
Net cash flows provided by operating activities |
|
51 |
|
75 |
|
129 |
|
(3 |
) |
252 |
|
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Cash Flows From Investing Activities |
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Capital and investment expenditures |
|
|
|
(79 |
) |
(21 |
) |
|
|
(100 |
) |
||||||||||
Investments in and advances to Q-Chem |
|
|
|
|
|
(18 |
) |
|
|
(18 |
) |
||||||||||
Other investing cash flow activity |
|
(30 |
) |
|
|
|
|
30 |
|
|
|
||||||||||
Net cash flows used in investing activities |
|
(30 |
) |
(79 |
) |
(39 |
) |
30 |
|
(118 |
) |
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Cash Flows From Financing Activities |
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Increase in commercial paper, net |
|
54 |
|
|
|
|
|
|
|
54 |
|
||||||||||
Decrease in secured borrowings, net |
|
|
|
|
|
(100 |
) |
|
|
(100 |
) |
||||||||||
Decrease in other debt, net |
|
|
|
(1 |
) |
(13 |
) |
|
|
(14 |
) |
||||||||||
Distributions on members preferred interests |
|
(39 |
) |
|
|
|
|
|
|
(39 |
) |
||||||||||
Other distributions to members |
|
(36 |
) |
|
|
|
|
|
|
(36 |
) |
||||||||||
Contributions from members |
|
|
|
|
|
27 |
|
(27 |
) |
|
|
||||||||||
Net cash flows used in financing activities |
|
(21 |
) |
(1 |
) |
(86 |
) |
(27 |
) |
(135 |
) |
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Net Increase (Decrease) in Cash and Cash Equivalents |
|
|
|
(5 |
) |
4 |
|
|
|
(1 |
) |
||||||||||
Cash and Cash Equivalents at Beginning of Period |
|
|
|
12 |
|
31 |
|
|
|
43 |
|
||||||||||
Cash and Cash Equivalents at End of Period |
|
$ |
|
|
$ |
7 |
|
$ |
35 |
|
$ |
|
|
$ |
42 |
|
|||||
19
Note 11. Condensed Consolidating Financial Statements (continued)
Chevron Phillips Chemical Company LLC
Condensed Consolidating Statement of Cash Flows
For the six months ended June 30, 2003
(Unaudited)
Millions |
|
LLC |
|
LP |
|
Other |
|
Eliminations |
|
Total |
|
||||||||||
Cash Flows From Operating Activities |
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Net income (loss) |
|
$ |
(47 |
) |
$ |
(66 |
) |
$ |
(9 |
) |
$ |
75 |
|
$ |
(47 |
) |
|||||
Adjustments to reconcile net income (loss) to net cash flows provided by (used in) operating activities |
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Depreciation, amortization and retirements |
|
|
|
132 |
|
8 |
|
|
|
140 |
|
||||||||||
Undistributed equity in losses (income) of affiliates, net |
|
9 |
|
1 |
|
48 |
|
(75 |
) |
(17 |
) |
||||||||||
Changes in operating working capital |
|
(10 |
) |
(54 |
) |
(43 |
) |
|
|
(107 |
) |
||||||||||
Other operating cash flow activity |
|
(35 |
) |
63 |
|
6 |
|
|
|
34 |
|
||||||||||
Net cash flows provided by (used in) operating activities |
|
(83 |
) |
76 |
|
10 |
|
|
|
3 |
|
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Cash Flows From Investing Activities |
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Capital and investment expenditures |
|
|
|
(61 |
) |
(22 |
) |
|
|
(83 |
) |
||||||||||
Investments in and advances to Q-Chem |
|
|
|
|
|
(76 |
) |
|
|
(76 |
) |
||||||||||
Other investing cash flow activity |
|
(89 |
) |
|
|
|
|
89 |
|
|
|
||||||||||
Net cash flows used in investing activities |
|
(89 |
) |
(61 |
) |
(98 |
) |
89 |
|
(159 |
) |
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Cash Flows From Financing Activities |
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Increase in commercial paper, net |
|
140 |
|
|
|
|
|
|
|
140 |
|
||||||||||
Increase in secured borrowings, net |
|
|
|
|
|
10 |
|
|
|
10 |
|
||||||||||
Contributions from members |
|
32 |
|
|
|
89 |
|
(89 |
) |
32 |
|
||||||||||
Net cash flows provided by financing activities |
|
172 |
|
|
|
99 |
|
(89 |
) |
182 |
|
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Net Increase in Cash and Cash Equivalents |
|
|
|
15 |
|
11 |
|
|
|
26 |
|
||||||||||
Cash and Cash Equivalents at Beginning of Period |
|
|
|
9 |
|
30 |
|
|
|
39 |
|
||||||||||
Cash and Cash Equivalents at End of Period |
|
$ |
|
|
$ |
24 |
|
$ |
41 |
|
$ |
|
|
$ |
65 |
|
|||||
20
ITEM 2. Managements Discussion and Analysis of Financial Condition and Results of Operations
This discussion should be read in conjunction with the condensed consolidated financial statements and notes preceding this discussion, and with Managements Discussion and Analysis of Financial Condition and Results of Operations and the consolidated financial statements and notes included in CPChems Annual Report on Form 10-K for the year ended December 31, 2003.
Results of Operations
Millions |
|
Three
months ended |
|
Six months
ended |
|
||||||||
2004 |
|
2003 |
|
2004 |
|
2003 |
|
||||||
|
|
|
|
|
|
|
|
|
|
||||
Income (loss) before interest and taxes |
|
|
|
|
|
|
|
|
|
||||
Olefins & Polyolefins |
|
$ |
56 |
|
$ |
35 |
|
$ |
159 |
|
$ |
(40 |
) |
Aromatics & Styrenics |
|
48 |
|
20 |
|
62 |
|
23 |
|
||||
Specialty Products |
|
19 |
|
10 |
|
34 |
|
20 |
|
||||
Corporate & Other |
|
(6 |
) |
(13 |
) |
(11 |
) |
(17 |
) |
||||
Consolidated |
|
117 |
|
52 |
|
244 |
|
(14 |
) |
||||
Net interest expense and income taxes |
|
(20 |
) |
(17 |
) |
(39 |
) |
(33 |
) |
||||
Net income (loss) |
|
$ |
97 |
|
$ |
35 |
|
$ |
205 |
|
$ |
(47 |
) |
Net income for the three-month period ended June 30, 2004 was $97 million compared with $35 million during the same three-month period in 2003. Consolidated net sales revenues increased in the 2004 period on higher overall sales prices and volumes, while equity earnings improved $28 million, primarily attributable to increased earnings from Q-Chem and Saudi Chevron Phillips. Other income rose due to higher licensing and commission income. Cost of Goods Sold increased as a result of higher overall sales volumes and feedstock costs. Selling, General and Administrative (SG&A) was lower in 2004, as 2003 included certain legal and employee termination benefit charges described below.
Net income for the first six months of 2004 was $205 million, representing a $252 million improvement over the $47 million loss recorded in the same period in 2003. Consolidated net sales revenues increased in the 2004 period on higher overall sales prices and volumes, while equity earnings improved $49 million. Cost of Goods Sold rose, primarily due to the increase in sales volumes. SG&A was lower in 2004, as 2003 included certain legal and employee termination benefit charges described below.
Included in 2003 results were charges to SG&A expense for CPChems share of certain ChevronTexaco and ConocoPhillips legal settlements and accruals relating to CPChems facilities ($9 million for the three months and $13 million for the six months) and employee termination benefit charges totaling $9 million recorded in the second quarter in connection with announced workforce reductions. Also included in 2003 results was accelerated depreciation related to the closure of the UDEX benzene extraction unit at CPChems Port Arthur, Texas facility in October 2003 ($3 million for the three months and $6 million for the six months).
21
Income (loss) before interest and taxes
Olefins & Polyolefins
|
|
Three
months ended |
|
Six months
ended |
|
||||||||
Millions |
|
2004 |
|
2003 |
|
2004 |
|
2003 |
|
||||
Income (loss) before interest and taxes |
|
$ |
56 |
|
$ |
35 |
|
$ |
159 |
|
$ |
(40 |
) |
Income before interest and taxes for Olefins & Polyolefins totaled $56 million in the second quarter of 2004 compared with $35 million in the prior-year period. Higher revenues, primarily due to increased overall sales volumes, were partially offset by higher feedstock and turnaround costs. Equity earnings also increased, driven primarily by improved results from Q-Chem. Increased earnings from polyethylene and normal alpha olefins/polyalpha olefins were partially offset by lower earnings from ethylene.
Olefins & Polyolefins income before interest and taxes totaled $159 million for the six months of 2004, representing an increase of $199 million when compared to the same-period loss of $40 million in 2003. Higher revenues from increased overall sales prices and volumes were partially offset by higher feedstock costs. Earnings from most product lines, primarily ethylene, polyethylene and natural gas liquids, were higher in the 2004 period. Equity earnings also increased, driven by improved results from Q-Chem.
Included in 2003 earnings were charges for the ChevronTexaco and ConocoPhillips legal settlements and accruals totaling $9 million for the three-month period and $13 million for the six-month period.
Aromatics & Styrenics
|
|
Three
months ended |
|
Six months
ended |
|
||||||||
Millions |
|
2004 |
|
2003 |
|
2004 |
|
2003 |
|
||||
Income before interest and taxes |
|
$ |
48 |
|
$ |
20 |
|
$ |
62 |
|
$ |
23 |
|
Income before interest and taxes for Aromatics & Styrenics totaled $48 million in the second quarter of 2004 compared with $20 million in the prior-year period. Revenues increased across most product lines as a result of higher sales prices. Earnings improved in 2004 on significantly higher benzene prices.
Aromatics & Styrenics income before interest and taxes totaled $62 million for the six months of 2004 compared with $23 million in the same period in 2003. Revenues increased across most product lines as a result of higher sales prices. Earnings benefited in 2004 primarily from higher benzene prices. Paraxylene earnings were down due to lower margins, primarily the result of higher feedstock costs. Improved results in the 2004 period were also partially attributable to the actions taken in 2003 to close the UDEX unit and idle the Port Arthur cumene plant.
Included in 2003 results was accelerated depreciation related to the closure of the UDEX unit totaling $3 million for the three-month period and $6 million for the six-month period.
22
Specialty Products
|
|
Three
months ended |
|
Six months
ended |
|
||||||||
Millions |
|
2004 |
|
2003 |
|
2004 |
|
2003 |
|
||||
Income before interest and taxes |
|
$ |
19 |
|
$ |
10 |
|
$ |
34 |
|
$ |
20 |
|
Income before interest and taxes for Specialty Products was $19 million in the three-month period ended June 30, 2004 compared with $10 million in the same period in 2003, and $34 million compared with $20 million for the six-month periods in 2004 and 2003, respectively. Earnings for Ryton® polyphenylene sulfide polymers increased in both 2004 periods primarily due to higher sales volumes and lower operating expenses. Specialty Chemicals earnings increased in the 2004 periods due to higher margins and sales volumes.
Corporate & Other
|
|
Three
months ended |
|
Six months
ended |
|
||||||||
Millions |
|
2004 |
|
2003 |
|
2004 |
|
2003 |
|
||||
Income (loss) before interest and taxes |
|
$ |
(6 |
) |
$ |
(13 |
) |
$ |
(11 |
) |
$ |
(17 |
) |
Corporate and Other included employee termination benefit charges totaling $9 million recorded in the second quarter of 2003 in connection with announced workforce reductions.
Outlook
CPChem maintains its focus on operational reliability, improving margins and increasing sales volumes as the global economy shows signs of recovery. Various industry analysts and consultants predict that while U.S. economic growth will accelerate in 2004, U.S. commodity chemicals consumption will be driven by recovery in the U.S. manufacturing sector, which is expected to follow improvement in the overall economy. Excess manufacturing capacity for most product lines continues to result in compressed margins and curtailed overall operating rates. While higher sales volumes and prices have bolstered CPChems earnings in the first half of 2004, persistent high energy and feedstock costs have also limited margin gains. Results from CPChems joint ventures in the Middle East continue to improve, due in part to good market conditions in Asia and favorable local feedstock costs, as well as increasing sales volumes from Q-Chem.
Liquidity and Capital Resources
Cash balances were $42 million at June 30, 2004 and $43 million at December 31, 2003, of which $35 million and $31 million, respectively, were held by foreign subsidiaries. CPChems objective is to minimize cash balances in its worldwide operations while utilizing its commercial paper program for daily operating requirements.
Operating Activities
Cash provided by operating activities totaled $252 million during the first six months of 2004 compared with $3 million during the same period in 2003. The improvement was driven primarily by higher earnings in 2004.
23
Investing Activities
Capital and investment expenditures totaled $100 million during the first six months of 2004, compared with $83 million in the prior-year period. Approximately $77 million of 2004 expenditures was invested in Olefins & Polyolefins, $17 million in Aromatics & Styrenics, $4 million in Specialty Products and the remaining $2 million in corporate-level expenditures. In addition, CPChem subscribed to $18 million of shares of Q-Chem in the 2004 period. In the first six months of 2003, CPChem advanced $76 million to Q-Chem. There were no such advances in 2004.
For the year 2004, CPChem expects to invest a total of approximately $250 million in capital and investment expenditures, to advance Q-Chem a total of approximately $10 million, and to subscribe to a total of $18 million of shares of Q-Chem.
See Note 6 of Notes to Condensed Consolidated Financial Statements for further discussion of the commitments to Q-Chem and for a discussion of a contingent funding commitment to Saudi Chevron Phillips.
Financing Activities
Cash used in financing activities totaled $135 million in the first six months of 2004 compared to $182 million provided by financing activities in the prior-year period. Commercial paper balances outstanding increased $54 million during the 2004 period compared with a $140 million increase during the 2003 period. Secured borrowings under the accounts receivable securitization program decreased $100 million during 2004. Also included in 2004 financing activities were $39 million of distributions on members preferred interests and $36 million of distributions to members to fund the members estimated federal and state income tax liability attributable to CPChem. Activities in the 2003 period included $32 million of contributions from members.
In the second quarter of 2004, CPChem renewed its $300 million trade receivables securitization agreement on terms substantially identical to those of the prior agreement. The new agreement expires on May 17, 2005. At June 30, 2004, $200 million was outstanding under the agreement.
On July 30, 2004, CPChem entered into an $800 million five-year credit facility with various banks that is used to provide backup committed credit for the commercial paper program. Effective with the closing of the new credit facility, CPChem terminated the existing $400 million 364-day and $400 million three-year credit facilities. The new credit agreement contains substantially the same terms as the terminated three-year agreement. There were no borrowings outstanding under either of the terminated credit agreements at June 30, 2004.
CPChem believes that cash requirements over the next 12 months will be funded through a combination of cash on hand, cash flows from operations, commercial paper and/or future debt issuances. CPChem is not aware of any conditions that exist as of the date of this report that would cause any of its debt obligations to be in or at risk of default. In addition, CPChem does not have any debt obligations whose maturities would be accelerated as the result of a credit rating downgrade.
Other
Contingent Liabilities. See Note 8 of Notes to Condensed Consolidated Financial Statements for a discussion of contingent liabilities.
New Accounting Pronouncements. See Note 2 of Notes to Condensed Consolidated Financial Statements for a discussion of new accounting pronouncements.
24
CAUTIONARY STATEMENTS REGARDING FORWARD-LOOKING INFORMATION
This Managements Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements within the meaning of the federal securities laws. Such statements can generally be identified with words and phrases such as believes, expects, anticipates, should, estimates or other words and phrases of similar meaning. Where CPChem expresses an expectation or belief as to future events or results, there can be no assurance that the expectation or belief will result, be achieved or be accomplished. Where any such forward-looking statement includes a statement of the assumptions or bases underlying such forward-looking statement, CPChem believes such assumptions or bases to be reasonable and to be made in good faith. Assumed facts or bases almost always vary from actual results, and the differences between assumed facts or bases and actual results can be material, depending on the circumstances. The more significant factors that, if erroneous, could cause actual results to differ materially from those expressed include, among others: the timing and duration of periods of expansion and contraction within the chemicals business; plans for the construction, modernization, start-up or de-bottlenecking of domestic and foreign chemical plants; prices of feedstocks, energy and products; force majeure events; accidents; labor relations; political risks; terrorist acts; war; changes in foreign and domestic laws, rules and regulations and the interpretation and enforcement thereof; regulatory decisions relating to taxes, the environment and human resources; the global economy; results of financing efforts; and overall financial market conditions. All forward-looking statements in this Form 10-Q are qualified in their entirety by the cautionary statements contained in this section. CPChem does not undertake to update, revise or correct any of the forward-looking information.
ITEM 3. Quantitative and Qualitative Disclosures about Market Risk
CPChems exposure to market risk is described in Item 7A of its Annual Report on Form 10-K for the year ended December 31, 2003. CPChem believes its exposure to market risk has not changed materially at June 30, 2004.
ITEM 4. Controls and Procedures
As of the end of the period covered by this report, and with the participation of management, CPChems Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of CPChems disclosure controls and procedures (as defined in Securities Exchange Act Rules 13a-15(e) and 15d-15(e)). Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that CPChems disclosure controls and procedures are effective in providing them with timely material information that is required to be disclosed in reports CPChem files under Section 13 or 15(d) of the Securities Exchange Act. There were no changes in CPChems internal control over financial reporting (as defined in Securities Exchange Act Rules 13a-15(f) and 15d-15(f)) that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, CPChems internal control over financial reporting.
25
ITEM 6. Exhibits and Reports on Form 8-K
(a) |
Exhibits |
|
|
|
|
|
10.1 |
Credit Agreement among Chevron Phillips Chemical Company LLC and Chevron Phillips Chemical Company LP, as Borrowers, and Barclays Bank Plc, The Royal Bank of Scotland Plc, Sumitomo Mitsui Banking Corporation, The Bank of Nova Scotia, The Bank of Tokyo-Mitsubishi Ltd., and certain lenders from time to time thereto, dated as of July 30, 2004 |
|
31.1 |
Certification of Chief Executive Officer pursuant to Rule 15d-14(a) of the Securities Exchange Act of 1934 |
|
31.2 |
Certification of Chief Financial Officer pursuant to Rule 15d-14(a) of the Securities Exchange Act of 1934 |
|
|
|
(b) |
Reports on Form 8-K - none |
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
CHEVRON PHILLIPS CHEMICAL COMPANY LLC |
|
|
|
|
|
|
|
Date: August 3, 2004 |
|
/s/ Greg G. Maxwell |
|
|
Greg G. Maxwell |
|
|
Senior Vice President, |
|
|
Chief Financial Officer and Controller |
26